A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published ...

Babies treated with nirsevimab had an 83% reduced risk of hospitalization due to RSV infection, researchers reported May 1 in The Lancet Child & Adolescent Health. The antibody treatment also ...

Almost 70 years after the discovery of the respiratory syncytial virus (RSV), vaccines and preventive treatments are giving babies a chance to beat the potentially deadly childhood infection.

As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But a new tool — nirsevimab, a protective antibody for infants — offers hope ...

A new antibody shot could help infants who contract respiratory ... significant lasting difference in what RSV, how it impacts our community." The treatment is also recommended for older adults ...

He is among those hoping to see far fewer struggling infants, thanks to new publicly funded RSV treatment available in Ontario for the first time this year. The treatment provides protective ...

Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the ...